---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-032076"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:40:14.462652+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Moleculin granted Australian patent for Annamycin lyophilizate; term until 2040

## Summary
- Australian Patent No. 2024203598 covers preliposomal Annamycin lyophilizates with improved stability and high purity.
- Base patent term extends to June 2040, subject to extension for regulatory approval.
- Patent family includes issued U.S., allowed European, and expected Canadian patents.
- Annamycin (naxtarubicin) has Fast Track & Orphan Drug designations from FDA for AML and STS lung mets, and EMA Orphan Drug for AML.

## SEC filing metadata
- accession: 0001437749-25-032076
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774925032076/0001437749-25-032076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774925032076/mbrx20251028_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-032076
- JSON: https://secwatch.observer/filing/0001437749-25-032076.json
- Plain text: https://secwatch.observer/filing/0001437749-25-032076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.